Endocyte Inc. closed a public offering of 20,535,714 shares, raising approximately $80.6 million in net proceeds.
The West Lafayette, Ind.-based biopharmaceutical company will use the funds to advance its product pipeline which includes Lu-PSMA-617 for the treatment of prostate cancer which is resistant to medical or surgical treatments and has spread to other parts of the body.
Jefferies LLC, Wells Fargo Securities LLC and Deutsche Bank Securities Inc. acted as joint book-running managers for the offering, with Wedbush Securities Inc. as co-lead manager.
